Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (9361)	7/9/1999 8:38:00 PM
From: Trevor Blake	Read Replies (1) \| Respond to of 57584

Rande, I have read your OCOM info (S.A.M.) with interest and will be doing some more research over the weekend. Have you taken a look at HIV for a similar play? HIV (Cel-Sci corporation)has a similar checkered past and a reverse split kept them in the frame. Their acronym is misleading because they have research on many fronts. Although people watch them because they are one of only 12 companies researching for an aids vaccine, their most immediate potential is for multikine. All trials to date show multikine to be an excellent drug, especially for head and neck tumors. Head and neck tumors are among the most treatable tumors, but multikine seems to offer a nice alternative to conventional therapy. I took a long position in HIV about 6 months ago after reading their clinical results. Since then, their activity in HIV vaccine research has brought in regular pump and dump daytrader activity from day-traders online. Each time the stock shoots up in a week from 2 to 3 and change and then gradually erodes back down to about 2. I have sold at 3 twice in the last few months and bought more at 2 1/8. As far as I can tell the company is sound, and their foundation research is exciting. I am much more comfortable passing an opinion on the clinical information than I am on the stock potential, so I would appreciate the opinions of yourself, Kevin, Banchee and others. Interestingly, the latest spike in June had a different pattern. My take is that European investors bought large blocks (HIV management has been on a european road show) and DTO jumped in when he saw the trades. The key point is that european investors quickly see the potential of multikine. Of course if their hiv vaccine worked out this would be a $200 stock overnight and the entremed gap up would become old hat. Their HIV research is less obvious and who knows which company will succeed in that? Your opinions appreciated. Thought I would pass it along. Be well